Research Topics
Species | Cecile RouleauSummaryAffiliation: Genzyme Corporation Country: USA Publications
| Collaborators
|
Detail Information
Publications
Endosialin protein expression and therapeutic target potential in human solid tumors: sarcoma versus carcinomaCecile Rouleau
Genzyme Corporation, Framingham, Massachusetts 01701, USA
Clin Cancer Res 14:7223-36. 2008..Endosialin/CD248/tumor endothelial marker 1 is expressed in stromal cells, endothelial cells, and pericytes in various tumors; however, few studies have focused on expression in malignant cells...
The systemic administration of lethal toxin achieves a growth delay of human melanoma and neuroblastoma xenografts: assessment of receptor contributionCecile Rouleau
Genzyme Corporation, Framingham, MA 01701, USA
Int J Oncol 32:739-48. 2008..The therapeutic potential of LeTx needs to be further investigated in non-melanoma tumor models expressing the ANTXR1/TEM8 and/or ANTXR2/CMG2 protein...- Endosialin/TEM 1/CD248 is a pericyte marker of embryonic and tumor neovascularizationRebecca G Bagley
Genzyme Corporation, 49 New York Avenue Framingham, MA 01701 9322, USA
Microvasc Res 76:180-8. 2008..Anti-endosialin antibodies may have value in identifying vasculature in malignant tissues. With the appropriate agent, targeting endosialin may interfere with blood vessel growth during tumor development... - Tumor endothelial marker 7 (TEM-7): a novel target for antiangiogenic therapyRebecca G Bagley
Genzyme Corporation, 49 New York Ave, Framingham, MA 01701, USA
Microvasc Res 82:253-62. 2011..These data demonstrate that TEM-7 is a vascular protein associated with angiogenic states. TEM-7 is a novel and attractive target for antiangiogenic therapy... - Human mesenchymal stem cells from bone marrow express tumor endothelial and stromal markersRebecca G Bagley
Genzyme Corporation, Framingham, MA 01701 9322, USA
Int J Oncol 34:619-27. 2009..Endosialin expression by both CAF and MSC further implies the potential contribution of MSC to tumor stroma via differentiation into tumor stromal fibroblasts... - Human endothelial precursor cells express tumor endothelial marker 1/endosialin/CD248Rebecca G Bagley
Genzyme Corporation, 49 New York Avenue, Framingham, MA 01701 9322, USA
Mol Cancer Ther 7:2536-46. 2008..The data presented here on endothelial genes that are up-regulated in tumor vasculature and in EPC support the hypothesis that the angiogenesis process in cancer can involve EPC... - Genz-644282, a novel non-camptothecin topoisomerase I inhibitor for cancer treatmentLeslie S Kurtzberg
Genzyme Corporation, Framingham, Massachussetts 01701, USA
Clin Cancer Res 17:2777-87. 2011.... - Bone marrow CFU-GM and human tumor xenograft efficacy of three antitumor nucleoside analogsRebecca G Bagley
Genzyme Corporation, Framingham, MA 01701, USA
Int J Oncol 34:1329-40. 2009..Bringing together bone marrow toxicity data, tumor cell line cytotoxicity data, and human tumor xenograft efficacy provides valuable information for the translation of preclinical findings to the clinic... - Endosialin: a novel malignant cell therapeutic target for neuroblastomaCecile Rouleau
Genzyme Corp, 49 New York Avenue, Framingham, MA 01701, USA
Int J Oncol 39:841-51. 2011..Human neuroblastoma xenograft tumors were found to be positive for endosialin. Our work suggests that endosialin may be a suitable therapeutic target for neuroblastoma... - Pericytes from human non-small cell lung carcinomas: an attractive target for anti-angiogenic therapyRebecca G Bagley
Genzyme Corporation, Framingham, MA 01701 9322, USA
Microvasc Res 71:163-74. 2006..Pericytes displayed invasive action against NSCLC clusters in the absence of other cell types. Perivascular cells contribute to the progression of disease and are an attractive target for anti-angiogenic therapy... - Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agentsLeslie S Kurtzberg
Genzyme Corporation, Framingham, MA 01701, USA
Cancer Chemother Pharmacol 64:1029-38. 2009..The bone marrow toxicity and human tumor xenograft activity of three tubulin-binding compounds, vincristine, paclitaxel, and tasidotin were compared... - Erufosine, an alkylphosphocholine, with differential toxicity to human cancer cells and bone marrow cellsRebecca G Bagley
Genzyme Corporation, 49 New York Ave, Framingham, MA 01701 9322, USA
Cancer Chemother Pharmacol 68:1537-46. 2011..To investigate the activity and myeloprotective properties of erufosine, a novel alkylphosphocholine (APC), on human malignant cells and normal bone marrow cells... - Bone marrow and tumor cell colony-forming units and human tumor xenograft efficacy of noncamptothecin and camptothecin topoisomerase I inhibitorsLeslie S Kurtzberg
Genzyme Corporation, 49 New York Avenue, Framingham, MA 01701, USA
Mol Cancer Ther 7:3212-22. 2008..This may be due to greater sensitivity of human bone marrow than mouse to the cytotoxicity of these agents. It may be possible to achieve similar levels of ARC-111 in patients as in mice allowing improved antitumor activity... - Endosialin is expressed in high grade and advanced sarcomas: evidence from clinical specimens and preclinical modelingCecile Rouleau
Genzyme Corporation, Framingham, MA, USA
Int J Oncol 39:73-89. 2011..These results demonstrate for the first time that endosialin is a suitable therapeutic target for poor prognosis and advanced disease... 
Characteristics of human Ewing/PNET sarcoma modelsBeverly A Teicher
Genzyme Corporation, 49 New York Avenue, Framingham, MA 01701, USA
Ann Saudi Med 31:174-82. 2011..Ewing PNET sarcomas are a rare disease where models are available...- Vascular gene expression in nonneoplastic and malignant brainStephen L Madden
Genetics and Genomics, 5 Mountain Rd, Framingham, MA 01701, USA
Am J Pathol 165:601-8. 2004..Additional characterization of this extensive brain endothelial cell gene expression database will provide unique molecular insights into vascular gene expression... - Protein tyrosine phosphatase PRL-3 in malignant cells and endothelial cells: expression and functionCecile Rouleau
Genzyme Corp, 1 Mountain Road, Framingham, MA 01701, USA
Mol Cancer Ther 5:219-29. 2006..These results indicate that PRL-3 is functional in both endothelial cells and malignant cells and further validate PRL-3 as a potentially important molecular target for anticancer therapy... - Pericytes and endothelial precursor cells: cellular interactions and contributions to malignancyRebecca G Bagley
Genzyme Corp, Framingham, Massachusetts 01701 9322, USA
Cancer Res 65:9741-50. 2005..These results support the notion that pericytes and EPC contribute to malignancy and that these cell types can be useful as cell-based models for tumor vascular development and selection of agents that may provide therapeutic benefit... - Murine endothelial cell lines as models of tumor endothelial cellsJennifer Walter-Yohrling
Genzyme Corporation, Framingham, Massachusetts 01701, USA
Clin Cancer Res 10:2179-89. 2004..These cells can be used in in vitro angiogenesis assays for evaluating the potential antiangiogenic properties and interspecies cross-reactivity of novel compounds... - Troponin I inhibits capillary endothelial cell proliferation by interaction with the cell's bFGF receptorLaurie Feldman
Laboratory for Cell and Molecular Biology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA
Microvasc Res 63:41-9. 2002..Preliminary data suggest that TnI may be competing with bFGF for interaction with the bFGF receptor on responsive cells...